{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:47:35Z","timestamp":1789832855117,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Insights Imaging"],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Immune checkpoint inhibitors, a type of intravenous immunotherapy targeting T cells, are being increasingly used in cancer treatment. They work by increasing the immune system\u2019s response to tumour cells, through blockade of inhibitory \u201ccheckpoint\u201d receptors. Immune checkpoint inhibitors commonly induce immune-related adverse events (irAEs) affecting multiple organ systems. Hypophysitis is strictly an endocrine irAE, but is the most common irAE identified on neuroimaging. True neurologic irAEs are rare and widely varied. Examples include meningitis, encephalitis, vasculitis, demyelinating syndromes and neuritis. Some neurologic irAEs are not associated with neuroimaging findings (for example, neuromuscular junction disorders), while in others, imaging findings are present in only a proportion of patients (for example, encephalitis). Diagnosing, or at least considering, a neurologic irAE is important for instigating the appropriate management and optimising patient outcomes. This educational review illustrates irAEs\u00a0that may be identified on neuroimaging and provides practical tips for optimising diagnosis, including relevant clinical considerations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Critical relevance statement<\/jats:title>\n            <jats:p>Immune checkpoint inhibitors, which are being increasingly used in cancer treatment, commonly induce immune-related adverse events. This educational review illustrates the range of immune-related adverse events for which neuroimaging plays a key role in diagnosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Key Points<\/jats:title>\n            <jats:p>\n              <jats:list list-type=\"bullet\">\n                <jats:list-item>\n                  <jats:p>Immune checkpoint inhibitors commonly result in immune-related adverse events (irAEs) affecting multiple organ systems.<\/jats:p>\n                <\/jats:list-item>\n                <jats:list-item>\n                  <jats:p>Hypophysitis, the most common irAE identified on neuroimaging, is characterised by transient pituitary enlargement.<\/jats:p>\n                <\/jats:list-item>\n                <jats:list-item>\n                  <jats:p>True neurologic irAEs are rare and include meningitis, encephalitis, vasculitis, demyelination and neuritis.<\/jats:p>\n                <\/jats:list-item>\n                <jats:list-item>\n                  <jats:p>An understanding of the overall clinical picture is important for supporting the diagnosis.<\/jats:p>\n                <\/jats:list-item>\n              <\/jats:list>\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s13244-025-01999-3","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T15:23:46Z","timestamp":1749741826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Neuroimaging features of immune-related adverse events due to immune checkpoint inhibitor therapy"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8176-3015","authenticated-orcid":false,"given":"Arian","family":"Lasocki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Spain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"1999_CR1","doi-asserted-by":"crossref","unstructured":"Jayathilaka B, Mian F, Franchini F et al (2025) Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review. Br J Cancer 132:51\u201357","DOI":"10.1038\/s41416-024-02887-1"},{"key":"1999_CR2","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA et al (2022) Immune checkpoint inhibitors in cancer therapy. Curr Oncol 29:3044\u20133060","journal-title":"Curr Oncol"},{"key":"1999_CR3","doi-asserted-by":"crossref","unstructured":"Fletcher K, Johnson DB (2024) Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update. J Immunother Cancer 12:e008591","DOI":"10.1136\/jitc-2023-008591"},{"key":"1999_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23\u201334","journal-title":"N Engl J Med"},{"key":"1999_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M et al (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1\u20138","journal-title":"Eur J Cancer"},{"key":"1999_CR6","doi-asserted-by":"crossref","unstructured":"Guidon AC, Burton LB, Chwalisz BK et al (2021) Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer 9:e002890","DOI":"10.1136\/jitc-2021-002890corr1"},{"key":"1999_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/1754-9485.13396","volume":"66","author":"G No\u00eb","year":"2022","unstructured":"No\u00eb G, Cardin A, Lasocki A (2022) Part 1: Imaging findings of common immune checkpoint inhibitor-related adverse effects. J Med Imaging Radiat Oncol 66:495\u2013501","journal-title":"J Med Imaging Radiat Oncol"},{"key":"1999_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563\u2013580","journal-title":"Nat Rev Clin Oncol"},{"key":"1999_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","volume":"19","author":"A Faje","year":"2016","unstructured":"Faje A (2016) Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19:82\u201392","journal-title":"Pituitary"},{"key":"1999_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.836859","volume":"12","author":"S Jessel","year":"2022","unstructured":"Jessel S, Weiss SA, Austin M et al (2022) Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function. Front Oncol 12:836859","journal-title":"Front Oncol"},{"key":"1999_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1530\/EJE-19-0238","volume":"181","author":"A Faje","year":"2019","unstructured":"Faje A, Reynolds K, Zubiri L et al (2019) Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol 181:211\u2013219","journal-title":"Eur J Endocrinol"},{"key":"1999_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148","journal-title":"Eur J Cancer"},{"key":"1999_CR13","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721\u20131728","journal-title":"JAMA Oncol"},{"key":"1999_CR14","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","volume":"30","author":"M Touat","year":"2017","unstructured":"Touat M, Talmasov D, Ricard D et al (2017) Neurological toxicities associated with immune-checkpoint inhibitors. Curr Opin Neurol 30:659\u2013668","journal-title":"Curr Opin Neurol"},{"key":"1999_CR15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ et al (2022) Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 19:254\u2013267","journal-title":"Nat Rev Clin Oncol"},{"key":"1999_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejca.2019.06.020","volume":"119","author":"A Mekki","year":"2019","unstructured":"Mekki A, Dercle L, Lichtenstein P et al (2019) Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy. Eur J Cancer 119:44\u201356","journal-title":"Eur J Cancer"},{"key":"1999_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.crad.2020.12.028","volume":"76","author":"A Lasocki","year":"2021","unstructured":"Lasocki A, Iravani A, Galligan A (2021) The imaging of immunotherapy-related hypophysitis and other pituitary lesions in oncology patients. Clin Radiol 76:325\u2013332","journal-title":"Clin Radiol"},{"key":"1999_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1295865","volume":"14","author":"A Galligan","year":"2023","unstructured":"Galligan A, Iravani A, Lasocki A et al (2023) Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis. Front Endocrinol 14:1295865","journal-title":"Front Endocrinol"},{"key":"1999_CR19","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/1754-9485.13391","volume":"66","author":"G No\u00eb","year":"2022","unstructured":"No\u00eb G, Cardin A, Lasocki A (2022) Part 2: Imaging findings of uncommon but important immune checkpoint inhibitor-related adverse effects. J Med Imaging Radiat Oncol 66:502\u2013507","journal-title":"J Med Imaging Radiat Oncol"},{"key":"1999_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101011","volume":"44","author":"A Farina","year":"2024","unstructured":"Farina A, Villagr\u00e1n-Garc\u00eda M, Fourier A et al (2024) Diagnostic and prognostic biomarkers in immune checkpoint inhibitor-related encephalitis: a retrospective cohort study. Lancet Reg Health Eur 44:101011","journal-title":"Lancet Reg Health Eur"},{"key":"1999_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1634\/theoncologist.2019-0083","volume":"25","author":"SR Schoenfeld","year":"2020","unstructured":"Schoenfeld SR, Aronow ME, Leaf RK et al (2020) Diagnosis and management of rare immune-related adverse events. Oncologist 25:6\u201314","journal-title":"Oncologist"},{"key":"1999_CR22","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jocn.2020.01.055","volume":"74","author":"A Lasocki","year":"2020","unstructured":"Lasocki A, Smith K (2020) Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma. J Clin Neurosci 74:240\u2013241","journal-title":"J Clin Neurosci"},{"key":"1999_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40425-018-0318-x","volume":"6","author":"L Cafuir","year":"2018","unstructured":"Cafuir L, Lawson D, Desai N et al (2018) Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab. J Immunother Cancer 6:11","journal-title":"J Immunother Cancer"},{"key":"1999_CR24","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/neuonc\/noaa030","volume":"22","author":"TJ Kaufmann","year":"2020","unstructured":"Kaufmann TJ, Smits M, Boxerman J et al (2020) Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. Neuro Oncol 22:757\u2013772","journal-title":"Neuro Oncol"},{"key":"1999_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/19714009221114440","volume":"36","author":"A Lasocki","year":"2023","unstructured":"Lasocki A, Caspersz L, McArthur GA (2023) Prospective comparison of volumetric post-contrast T1-sampling perfection with application optimized contrasts by using different flip angle evolutions and magnetization-prepared rapid acquisition with gradient echo in patients with metastatic melanoma. Neuroradiol J 36:169\u2013175","journal-title":"Neuroradiol J"},{"key":"1999_CR26","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1007\/s00330-015-3975-x","volume":"26","author":"NN Kammer","year":"2016","unstructured":"Kammer NN, Coppenrath E, Treitl KM et al (2016) Comparison of contrast-enhanced modified T1-weighted 3D TSE black-blood and 3D MP-RAGE sequences for the detection of cerebral metastases and brain tumours. Eur Radiol 26:1818\u20131825","journal-title":"Eur Radiol"},{"key":"1999_CR27","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s11060-016-2185-y","volume":"129","author":"CH Suh","year":"2016","unstructured":"Suh CH, Jung SC, Kim KW et al (2016) The detectability of brain metastases using contrast-enhanced spin-echo or gradient-echo images: a systematic review and meta-analysis. J Neurooncol 129:363\u2013371","journal-title":"J Neurooncol"},{"key":"1999_CR28","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/CMR.0000000000000683","volume":"30","author":"A Lasocki","year":"2020","unstructured":"Lasocki A, Kee D (2020) Clinical and radiological evolution of cerebral amyloid angiopathy-related inflammation in the context of anti-PD-1 immunotherapy. Melanoma Res 30:608\u2013612","journal-title":"Melanoma Res"},{"key":"1999_CR29","first-page":"340","volume":"6","author":"D Anderson","year":"2019","unstructured":"Anderson D, Beecher G, Nathoo N et al (2019) Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors. Neurooncol Pract 6:340\u2013345","journal-title":"Neurooncol Pract"},{"key":"1999_CR30","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.3174\/ajnr.A4387","volume":"36","author":"M Park","year":"2015","unstructured":"Park M, Lee SK, Choi J et al (2015) Differentiation between cystic pituitary adenomas and Rathke cleft cysts: a diagnostic model using MRI. AJNR Am J Neuroradiol 36:1866\u20131873","journal-title":"AJNR Am J Neuroradiol"}],"container-title":["Insights into Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-025-01999-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13244-025-01999-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-025-01999-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T15:23:48Z","timestamp":1749741828000},"score":1,"resource":{"primary":{"URL":"https:\/\/insightsimaging.springeropen.com\/articles\/10.1186\/s13244-025-01999-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1999"],"URL":"https:\/\/doi.org\/10.1186\/s13244-025-01999-3","relation":{},"ISSN":["1869-4101"],"issn-type":[{"value":"1869-4101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional ethics committee approval was received (QA\/108346\/PMCC), including approval for a waiver of patient consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Institutional ethics committee approval was received for a waiver of patient consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}